Why short stature is beneficial in duchenne muscular dystrophy

Muscle and Nerve

Volumn 48, Issue 3, 2013, Pages 336-342

  Bodor, Marko ^a,b   Mcdonald, Craig M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Duchenne muscular dystrophy; Growth; Sarcolemma; Stature; Stress

Indexed keywords

DYSTROPHIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; GROWTH HORMONE DEFICIENCY; GROWTH INHIBITION; MATHEMATICAL MODEL; MOUSE; MUSCLE CELL; MUSCLE STRENGTH; MUSCLE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SARCOLEMMA; SHORT STATURE;

DUCHENNE MUSCULAR DYSTROPHY; GROWTH; SARCOLEMMA; STATURE; STRESS;

ANIMALS; BIOMETRY; BODY HEIGHT; BODY WEIGHT; CHILD; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MALE; MATHEMATICS; MICE; MICE, INBRED MDX; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SARCOLEMMA; TIME FACTORS;

EID: 84883052548     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23793     Document Type: Article

References (53)

1. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012;45:796-802. doi:10.1002/mus.23272.
2. McDonald CM, Han JJ, Mah JK, Carter GT. Corticosteroids and duchenne muscular dystrophy: Does earlier treatment really matter? Muscle Nerve 2012;45:777-779. doi:10.1002/mus.23304.
3. Zatz M, Rapaport D, Vainzof M, Rocha JM, Pavanello Rde C, Colletto GM, et al. Relation between height and clinical course in Duchenne muscular dystrophy. Am J Med Genet 1988;29:405-410.
4. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The CINRG Duchenne Natural History Study: Glucocorticoid treatment preserves clinically-meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly-used clinical trial outcome measures. Muscle Nerve (in press).
5. Mah JK, Hu F, McDonald CM. Short stature prolonged ambulation in boys with Duchenne muscular dystrophy. Can J Neurol Sci 2012;39:S13.
6. Thompson DW. On growth and form. In: Bonner JT, editor. Cambridge: Cambridge University Press; 2004.
7. Arkin AM. Absolute muscle power: the internal kinesiology of muscle. Thesis. Department of Orthopedic Surgery. State University of Iowa, 1939.
8. Von Recklinghausen H. Gliedermechanik and Lahmungsprothesen. Berlin: Springer-Verlag; 1920.
9. Lietzke MH. Relation between weightlifting totals and body weight. Science 1956;124:486-487.
10. Markovic G, Sekulic D. Modeling the influence of body size on weightlifting and powerlifting performance. Coll Antropol 2006;30:607-613.
11. List of World Records in Olympic weightlifting. http://en.wikipedia.org/wiki/List_of_world_records_in_Olympic_weightlifting, accessed 6/8/2012.
12. Dirks JH, Federle W. Fluid based adhesion in insects - principles and challenges. Soft Matter 2011;7:11047-11053.
13. Asmussen E, Heeboll-Nielsen K. A dimensional analysis of physical performance and growth in boys. J Appl Physiol 1955;7:593-603.
14. Welsman JR, Armstrong N. Interpreting exercise performance data in relation to body size. In: Armstrong N, Van Mechelen W, editors. Pediatric exercise science and medicine. New York: Oxford University Press; 2008.
15. Center for Disease Control and Prevention. http://www.cdc.gov/growthcharts/clinical_charts.htm, accessed 8/8/2012.
16. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations. Muscle Nerve 2010;42:966-974.
17. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-716.
18. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G, et al. Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences. PLoS Curr 2012 [Epub ahead of print].
19. McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995;74(Suppl):S70-S92.
20. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006;7:762-773.
21. Karpati G, Carpenter S, Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988;11:795-803.
22. Oertel G. Morphometric analysis of normal skeletal muscles in infancy, childhood and adolescence. An autopsy study. J Neurol Sci 1988;88:303-313.
23. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988;52:503-513.
24. Minetti C, Ricci E, Bonilla E. Progressive depletion of fast alpha-actinin-positive muscle fibers in Duchenne muscular dystrophy. Neurology 1991;41:1977-1981.
25. Engel AG, Ozawa E. Muscular dystrophies. In: Engel AG, Franzini-Amstrong C, editors. Myology. New York: McGraw Hill; 2004.
26. Burke RE, Tsairis P. Anatomy and innervation ratios in motor units of cat gastrocnemius. J Physiol 1973;234:749-765.
27. Totsuka T, K Watanabe, S Kiyono. Masking of a dystrophic symptom in genotypically dystrophic-dwarf mice. Proc Japan Acad 1981;57B:109-113.
28. Valentine BA, Cooper BJ, deLahunta A, OQuinn R, Blue JT. Canine X-linked muscular dystrophy: clinical studies. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 1988;88:69-81.
29. Nakamura A, Takeda S. Mammalian models of Duchenne muscular dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol 2011;2011:184393.
30. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 2012;23:85-108.
31. de Lima AR, Nyengaard JR, Jorge AA, Balieiro JC, Peixoto C, Fioretto ET, et al. Muscular dystrophy-related quantitative and chemical changes in adenohypophysis GH-cells in golden retrievers. Growth Horm IGF Res 2007;17:480-491.
32. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007;21:2195-2204.
33. Hagen-Poiseuille Equation. http://en.wikipedia.org/wiki/Hagen%E2%80%93Poiseuille_equation, accessed 7/30/2012.
34. De Angelis K, Wichi RB, Jesus WR, Moreira ED, Morris M, Krieger EM, et al. Exercise training changes autonomic cardiovascular balance in mice. J Appl Physiol 2004;96:2174-2178.
35. Young-Laplace Equation. http://en.wikipedia.org/wiki/Young%E2%80%93Laplace_equation, accessed 10/4/2012.
36. Kleiber M. Body size and metabolic rate. Physiol Rev 1947;27:511-541.
37. Zatz M, Betti RT. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. Am J Med Genet 1986;24:567-572.
38. Badalian LO, Temin PA, Kamennykh LN, Zavadenko NN, Nikanorova MIu, Arkhipov BA, et al. [A benign variant of the course of Duchenne muscular dystrophy in a child with short stature]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91:94-97. Russian.
39. Ghafoor T, Mahmood A, Shams S. Duchenne muscular dystrophy with associated growth hormone deficiency. J Coll Physicians Surg Pak 2003;13:722-723.
40. Zatz M, Betti RT, Frota-Pessoa O. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. Am J Med Genet 1986;24:549-566.
41. Coakley JH, Moorcraft J, Hipkin LJ, Smith CS, Griffiths RD, Edwards RH. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 1988;51:1551-1557.
42. Griggs RC, Moxley RT III, Mendell JR, Fenichel GM, Brooke MH, Miller PJ, et al. Randomized, double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve 1990;13:1169-1173.
43. Karpati G, Jacob P, Carpenter S, Prescott S. Hypophysectomy mitigates skeletal muscle fiber damage in hamster dystrophy. Ann Neurol 1985;20:451-460.
44. Rudman D, Chyatte SB, Patterson JH, Gerron GG, O'Beirne I, Barlow J, et al. Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy. J Clin Invest 1972;51:1118-1124.
45. Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 2012;22:1046-1056.
46. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93. Review.
47. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189. Review. Erratum in: Lancet Neurol 2010;9:237.
48. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: Report from International Working Group Meetings. Clin Invest 2011;1:1217-1235.
49. Biggar WD, Harris VA, Eliasoph l, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
50. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011;21:129-133. Review.
51. Peterson JM, Bakkar N, Guttridge DC. NF-κB signaling in skeletal muscle health and disease. Curr Top Dev Biol 2011;96:85-119. Review.
52. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1119-1122.
53. Bremer AA, Mietus-Snyder ML, Lustig RH. State of the art: toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012;129:557-570.